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Previews(Ru¨ckle et al., 2006), and the development
of PI3Kg-selective compounds has been
slower than other target profiles. Although
the conclusions of Schmid et al. (2011)
need to be validated in other models,
the current data support the novel con-
clusion that the antiinflammatory potential
of PI3Kg inhibitors might be harnessed
to disrupt the tumor microenvironment
and slow the progression of cancer. The
fact that most solid tumor cells do not
express PI3Kg should limit the de-
velopment of resistance to PI3Kg inhibi-
tors. These considerations should
increase momentum for PI3Kg inhibitor
programs. To be sure, there remain
challenges to developing treatments tar-
geting cancer inflammation. Should such
agents be given as preventive therapy,
or will they be effective in treating estab-
lished malignancies? These questions
can be addressed initially through addi-tional preclinical studies. If PI3Kg-
targeted agents can limit the growth of
established tumors, an important im-
plication is that drugs targeting all class I
PI3Ks (or just PI3Ka and PI3Kg) should
be more effective than selective PI3Ka
inhibitors, even in patients whose tumors
are driven by PI3KCA mutations.
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The tumor environment consists of tumor-associated cells, such as macrophages, fibroblasts, and extra-
cellular matrix, and has an important impact on tumor progression. In this issue of Cancer Cell, Samuel
et al. show that ROCK-driven actomyosin contractility increases tissue stiffness affecting epidermal homeo-
stasis, as well as tumor growth and progression.Tissues consist of cells and extracellular
matrix (ECM), and cells are tightly linked to
their extracellular environment through
adhesion receptorssuchas integrins.Within
a tissue, remodeling of the ECM can occur
as part of normal physiological processes
or in disease. ECM remodeling involves
both the physical force of tension acting
on the ECM and enzymatic action; for
example, by extracellular proteases or
enzymes that crosslink ECM components
such as collagen. An imbalance in the
relationship between cells and the extracel-
lular environment is found in diseases such
as cancer, and there is strong evidencethat increased tissue stiffness contributes
to tumor progression (Levental et al., 2009;
Paszek et al., 2005). Indeed, increased
tissue stiffness is the basis of physical
examination by palpation for cancer. Tissue
stiffening may result from ECM remodeling
that drives integrin clustering at the cell
surface and subsequent cytoskeletal
changes, resulting inchangesof intracellular
tension. Intracellular tension arises through
theactionofmyosin II in generatingactomy-
osin contractility. Actomyosin contractility
hasmultipleother roles inaddition tomuscle
contraction. It is essential for cyokinesis in
mitosis, cell adhesion, cell shape, and cellmovement (Vicente-Manzanares et al.,
2011). The level of actomyosin contractility
in tumor cells is a key determinant of
different modes of cell movement (Sanz-
Moreno and Marshall, 2010). An important
regulator of actomyosin contractility is the
familyofRho-associatedcoiled-coil forming
protein serine/threonine kinases (ROCKI
and ROCKII) that are activated by Rho
GTPases RhoA and RhoC. ROCKI and II
generate contractile force through phos-
phorylation of the myosin-binding subunit
of myosin phosphatase (MYPT1), LIM
kinase 2 (LIMK2), and possibly myosin
regulatory light chain (MLC2) (Figure 1A).19, June 14, 2011 ª2011 Elsevier Inc. 695
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Figure 1. Signaling Pathways to Actomyosin Contractility and Effects of Increased
Intracellular Tension on Skin Homeostasis and Tumor Growth
(A) Regulation of actomyosin contractility by Rho family GTPases. Phosphorylation of MLC2, the regula-
tory subunit of myosin, activates the holoenzyme and generates actomyosin contractility. Rho family
GTPases regulate myosin phosphatase, Rho kinase (ROCK), or myotonic dystrophy kinase-related
Cdc42 binding kinase (MRCK), which phosphorylate the myosin-binding subunit of myosin phosphatase
(MYPT1), inactivating myosin phosphatase to prevent dephosphorylation of MLC2. Actomyosin contrac-
tility can be blocked by blebbistatin, which directly inhibits Myosin II ATPase activity or treatment with
ROCK inhibitors such as Y27632, which lead to increased myosin phosphatase activity.
(B) K14-driven expression of ROCK:ER in mouse skin induces actomyosin contractility, resulting in
increased collagen deposition and tissue stiffness. Intracellular signaling is promoted by the engagement
of integrins and activation of focal adhesion kinase (FAK) leading to b-catenin-induced gene expression.
Expression of ROCK:ER in DMBA/TPA-treated mice induces a significant increase in tumor burden
compared with controls.
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PreviewsThe skin is constantly exposed to envi-
ronmental stresses, and therefore a con-
stant remodeling process is required to
maintain barrier integrity and protection
from external forces. Thus, it provides
a good system to study the effects of
intracellular tension. Samuel et al. (2009)
previously generated a mouse model that
expresses a chimeric protein, ROCK:ER,
consisting of the kinase domain of human
ROCK II fused to a tamoxifen-regulated
mutant estrogen receptor (ER) and en-
hanced green fluorescent protein (EGFP)
under the control of the K14 promoter.
Samuel et al. (2011) now use this model
to study ROCK-induced actomyosin con-
tractility in tissue homeostasis and tumor
progression. Upon induction of ROCK
activity, Samuel et al. (2011) observed an
increase in collagen density and tissue
stiffness, as well as epidermal hyperprolif-
eration compared with wild-type skin
or skin expressing a kinase dead (KD)
version of the ROCK:ER protein. Inter-
estingly, this shows that ROCK:ER-
induced intracellular contractility affected
two seemingly different processes: ECM
remodeling and increased tissue stiffness
on one hand and cellular proliferation on
the other. The increased proliferation
appears to be a consequence of enhanced
bcatenin signaling. b-Catenin is known to
be a regulator of epidermal proliferation
and is responsive to mechanical tension.
Samuel et al. (2011) showed that, following
induction of ROCK activity in skin, b-cate-
nin localizationchanged frommembranous
to cytoplasmic and nuclear, and overall
b-catenin levels increased significantly. In
contrast, E-cadherin,withwhichb-catenin
interacts at cell-cell junctions, remained at
the cell membrane. Importantly, nuclear
b-catenin was found to be in the activated
form, and this was associated with an
increase in glycogen synthase kinase-3
(GSK-3b) phosphorylation. To confirm
the role of b-catenin in ROCK-induced hy-
perproliferation, b-catenin expressionwas
ablated in the skin, which resulted in
reduced proliferation and expression of
the target genes, CD44 and CyclinD1.
To show that the consequences of
increased ROCK activity were a result of
increased actomyosin contractility, the
authors tested whether inhibiting media-
tors of contractility downstream of ROCK
would block the induced epidermal hyper-
proliferation. Indeed, application of an
inhibitor of myosin II ATPase activity
Cancer Cell
Previews(blebbistatin) or an inhibitor of LIMK,
a kinase that acts downstream of ROCK
to promote actin assembly, blocked skin
thickening and reduced b-catenin levels
in K14-ROCK:ER mice. Similarly, the in-
crease in collagen deposition was found
to be reduced.
To test whether ROCK activation would
impact tumor growth and progression,
skin papillomas were induced by two-
step chemical tumorigenesis using dime-
thylbenz[a]anthracene (DMBA) and 12-O-
tetradecanoylphorbol-13-acetate (TPA).
Through a mechanism involving mutation
of HRAS and subsequent MAP-kinase
activation, skin papillomas appear and a
small proportion progress to invasive car-
cinomas. When the inducible ROCK:ER
micewere used in the two-stage chemical
carcinogenesis protocol, induction of
ROCK activity increased total papilloma
burden and accelerated progression to
carcinomas compared with controls.
Moreover, total and nuclear b-catenin
levels were significantly increased in pap-
illomas in the ROCK:ER mice, indicating
that the pathways regulating skin thick-
ening are also important during tumor
progression. Interestingly, the authors
showed that simultaneous treatment of
mouse skin with DMBA/TPA and the
ROCK inhibitor Y-27632 resulted in a
significantly lower papilloma burden anda lower conversion rate. It will be of great
interest to determine the effects of block-
ing ROCK activity on established papillo-
masandcarcinomas. Importantly, Samuel
et al. (2011) provide evidence that ROCK
signaling is frequently upregulated in
human skin carcinomas. Further work will
be required to provide a detailed picture
of the levels of ROCK and ROCK signaling
to tumor grade and to extend these
studies to other tumor types.
Without doubt, Samuel et al. (2011)
have provided strong evidence for ROCK-
mediated intracellular contractility driving
tumorigenesis by affecting ECM deposi-
tion, remodeling, and tissue stiffness.
Importantly, they show that increased
tissue stiffness results from increased
collagen deposition and crosslinking fol-
lowing increased actomyosin contractility
(Figure 1B). Why there is an increased
collagen deposition remains unclear,
whereas the mechanism for an increase in
levels of b-catenin and its transcriptional
activity may depend on increased integrin
signaling (Figure 1B). In the experimental
systemused in thisstudy,elevatedactomy-
osin contractility is generated in the tumor
cells themselves; however, other work
suggests that tumor-associated cells such
as carcinoma-associated fibroblasts can
generate actomyosin contractility for extra-
cellular matrix remodeling (Gaggioli et al.,Cancer Cell2007). Furthermore, there is evidence that
some cancers may harbor mutations that
reduce actomyosin contractility (Brognard
et al., 2011). Thus, the study of the roles of
actomyosin contractility is likely to generate
many new insights into tumor biology.REFERENCES
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Two recent Cancer Cell articles report the discovery of reciprocal feedback regulation between androgenic
and PTEN loss/PI3K-AKT signaling in prostate cancer. Both studies link endocrine regulation with a common
oncogenic pathway, which led to the development of a combination therapeutic approach with immediate
application in prostate cancer.The exquisite sensitivity of the prostate
gland to androgenic steroids has provided
a foothold for the development of sys-temic prostate cancer therapy for more
than seventy years (Huggins and Hodges,
1941). A sustainedstrategic approach thatfocused on inhibiting this unique signaling
pathway led to the use of androgen-depri-
vation and antiandrogenic therapies for19, June 14, 2011 ª2011 Elsevier Inc. 697
